Coverage
-
January 24, 2019
The full First Circuit on Wednesday refused to reconsider a panel decision decertifying a class of buyers who allegedly overpaid for Allergan's ulcerative colitis drug Asacol, in what could be another blow against certification for proposed classes that may contain uninjured members.
5 other articles on this case.
View all »